# CM-101 in PSC Patients -The SPRING Study

> **NCT04595825** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **ChemomAb Ltd.** · enrollment: 68 (estimated)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **BIOLOGICAL:** Anti-human CCL24 monoclonal antibody (CM-101)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04595825
- **Lead sponsor:** ChemomAb Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2024-09
- **Final completion:** 2025-09
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2024-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04595825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04595825, "CM-101 in PSC Patients -The SPRING Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04595825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*